As life sciences companies proliferate and mature, increased opportunities and risks arise with respect to companies in urgent need of reinvestment. In this webinar, WilmerHale panelists will discuss life sciences debt finance, financial restructuring and distressed acquisition transactions from the perspectives of both life sciences companies and their investors.
The debt finance component of the discussion will focus on revenue and royalty sale and finance transactions, as well as structured loans and loans with revenue and royalty participation components. The financial restructuring component will address intellectual property-centered restructuring transactions and the unique ways that restructurings can preserve the value of life sciences companies’ most important assets in times of financial distress. The distressed acquisition component will take up the advantages and disadvantages of various acquisition strategies: equity versus asset purchases; purchases through bankruptcy section 363 sales and assignments for the benefit of creditors; and purchases through secured party rights under structured loans.
*CLE credit is not available for those who watch webinar recordings.
